Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Roivant Sciences's enterprise value is $21,690.38 Mil.
Roivant Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-1,281.96 Mil. Therefore, Roivant Sciences's EV-to-EBITDA for today is -16.92.
The historical rank and industry rank for Roivant Sciences's EV-to-EBITDA or its related term are showing as below:
ROIV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.46 Med: -4.25 Max: -0.88
Current: -16.92
During the past 6 years, the highest EV-to-EBITDA of Roivant Sciences was -0.88. The lowest was -17.46. And the median was -4.25.
ROIV's EV-to-EBITDA is ranked worse than 100% of 397
companies
in the Biotechnology industry
Industry Median: 12.31
vs ROIV: -16.92
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Roivant Sciences's PE Ratio (TTM) for today is calculated as:
Roivant Sciences's share price for today is $34.91.
Roivant Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Roivant Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Roivant Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's EV-to-EBITDA falls into.
Roivant Sciences's current Enterprise Value is $21,690.38 Mil.
Roivant Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,281.96 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIV) has a EV-to-EBITDA of -16.92 as of Jul. 15, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Roivant Sciences. According to the industry distribution chart, Roivant Sciences ranks #999999 out of 397 companies in the Biotechnology industry.
Is Roivant Sciences' EV-to-EBITDA too high?
Roivant Sciences' current EV-to-EBITDA is -16.92. Based on the distribution chart, Roivant Sciences ranks #999999 out of 397 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' EV-to-EBITDA compare to RPRX and BNTX?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #999999 out of 397 companies for EV-to-EBITDA. This places Roivant Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 12.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.31, based on 397 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Roivant Sciences. For the Biotechnology industry, the median EV-to-EBITDA is 12.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current EV-to-EBITDA is -16.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.15, compared to a current price of $34.91 — trading 213.1% above its estimated fair value. The current EV-to-EBITDA is -16.92. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current EV-to-EBITDA is -16.92 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (ROIV) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of $34.91 is trading 213.1% above its estimated GF Value™ of $11.15.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for ROIV:
EV-to-EBITDA: -16.92
GF Value™: $11.15 vs. price of $34.91 (213.1% above fair value)
No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score
Get the complete analysis for ROIV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIV has been successfully added to your 
